PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab -paclitaxel (FA) and nab -paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development. (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps4166
Publication URI: http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps4166
Type: Journal Article/Review
Parent Publication: Journal of Clinical Oncology
Issue: 15_suppl